Mobile

A study is to see if HIV-1 positive subjects currently taking an antiretroviral (ARV) regimen consisting of EVG/COBI/FTC/TDF (E/C/F/TDF) STR, Atripla® (also known as Sustiva®), cobicistat and atazanav...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005114-20

A study is to see if HIV-1 positive subjects currently taking an antiretroviral (ARV) regimen consisting of EVG/COBI/FTC/TDF (E/C/F/TDF) STR, Atripla® (also known as Sustiva®), cobicistat and atazanavir with Truvada® or ritonovir and atazanavir with Truvada® can safely switch to E/C/F/TAF STR without increasing the amount of HIV-1 in their blood

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is: • To evaluate the non-inferiority of switching to a TAF-Containing STR relative to maintaining TDF-Containing Regimens in Virologically-Suppressed HIV-1 positive subjects as determined by having HIV-1 RNA < 50 copies/mL at Week 48 (FDA Snapshot Analysis).

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection

Liens